These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Initial clinical experience with endocardial defibrillation using an implantable cardioverter/defibrillator with a triple-electrode system. Saksena S; Tullo NG; Krol RB; Mauro AM Arch Intern Med; 1989 Oct; 149(10):2333-9. PubMed ID: 2802898 [TBL] [Abstract][Full Text] [Related]
6. [Leadless pacemakers and subcutaneously implantable cardioverter defibrillators]. Stellbrink C; Hansky B; Meyer Zu Vilsendorf D Internist (Berl); 2018 Oct; 59(10):999-1010. PubMed ID: 30105398 [TBL] [Abstract][Full Text] [Related]
7. Transmembrane voltage changes produced by real and virtual electrodes during monophasic defibrillation shock delivered by an implantable electrode. Efimov IR; Cheng YN; Biermann M; Van Wagoner DR; Mazgalev TN; Tchou PJ J Cardiovasc Electrophysiol; 1997 Sep; 8(9):1031-45. PubMed ID: 9300301 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of noninvasive programmed stimulation for initiating ventricular tachyarrhythmias in patients with third-generation implantable cardioverter defibrillators. Kleiman RB; Callans DJ; Hook BG; Marchlinski FE Pacing Clin Electrophysiol; 1994 Sep; 17(9):1462-8. PubMed ID: 7991416 [TBL] [Abstract][Full Text] [Related]
9. Innovations in pulse generators and lead systems: balancing complexity with clinical benefit and long-term results. Saksena S; Krol RB; Kaushik RR Am Heart J; 1994 Apr; 127(4 Pt 2):1010-21. PubMed ID: 8160574 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants. Fromer M; Brachmann J; Block M; Siebels J; Hoffmann E; Almendral J; Ohm OJ; den Dulk K; Coumel P; Camm AJ Circulation; 1992 Aug; 86(2):363-74. PubMed ID: 1638705 [TBL] [Abstract][Full Text] [Related]
11. Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis. Barra S; Duehmke R; Providencia R; Marijon E; Boveda S; Virdee M; Heck P; Fynn S; Begley D; Grace A; Agarwal S Europace; 2018 Jan; 20(1):89-96. PubMed ID: 28031276 [TBL] [Abstract][Full Text] [Related]
12. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators. Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354 [TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of the effect of biphasic waveform defibrillation on ventricular pacing thresholds. Kudenchuk PJ; Poole JE; Dolack GL; Gleva MJ; Anderson J; Troutman C; Bardy GH J Cardiovasc Electrophysiol; 1997 May; 8(5):485-95. PubMed ID: 9160224 [TBL] [Abstract][Full Text] [Related]